RudaCure Inc. (CEO Yongho Kim), a bioventure specializing in pain drug development, has been selected as a newly certified '2025 Hi-Seoul Enterprise' by the Seoul Metropolitan Government and Seoul Business Agency (SBA).
The Hi-Seoul Enterprise certification is a program where Seoul Metropolitan Government comprehensively evaluates growth potential, profitability, and global capabilities to select and support promising SMEs in the region. Through this certification, RudaCure has officially been recognized for its drug development technology and business achievements.
In 2024, the average revenue of Hi-Seoul certified companies reached KRW 14.5 billion, with approximately 50% of certified companies expanding into 127 countries, generating annual exports of KRW 3.5 trillion. Currently, a total of 1,259 companies hold this certification, and certified companies enjoy various benefits including preferential selection for SBA-operated programs, marketing and overseas expansion support, and tax and financial advantages.
RudaCure's dry eye disease treatment RCI001 has recently obtained U.S. FDA Phase 2 clinical trial IND approval, signaling the beginning of the company's advancement into the global market. These results have validated the company's potential and capabilities, demonstrating synergy with the Hi-Seoul Enterprise certification and establishing a strong foundation for growth.
CEO Yongho Kim of RudaCure stated, "The Hi-Seoul Enterprise certification is meaningful as official recognition of RudaCure's innovative technology and growth potential in new drug development. We will leverage this momentum to secure global competitiveness and lead the pain therapeutics market through the development of innovative treatments."